Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

44.28 -15.50 (-25.93%)
Streaming Delayed Price Updated: 11:22 AM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Veracyte (VCYT) Q4 2025 Earnings Call Transcript ↗
Veracyte (VCYT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Veracyte Inc (NASDAQ:VCYT) Posts Strong Q4 Earnings Beat and Positive 2026 Outlook ↗
Via Chartmill
Topics Earnings
News headline image
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
From Veracyte
Via Business Wire
Veracyte Inc (NASDAQ:VCYT): A Prime GARP Stock with Strong Growth and a Sound Balance Sheet ↗
Via Chartmill
Veracyte Inc. (NASDAQ:VCYT) Emerges as a Prime Affordable Growth Candidate ↗
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability
On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025... 
Via MarketMinute
Topics Artificial Intelligence Death
News headline image
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Inc (NASDAQ:VCYT) Emerges as a Top Affordable Growth Stock ↗
Veracyte (VCYT) exemplifies the GARP strategy, offering strong growth, a reasonable industry price, and a solid debt-free financial foundation. 
Via Chartmill
News headline image
Veracyte Inc (NASDAQ:VCYT): A GARP Stock With Strong Growth and a Reasonable Price ↗
Veracyte (VCYT) exemplifies GARP investing with strong cancer diagnostic growth, reasonable valuation vs. biotech peers, and a debt-free financial foundation. 
Via Chartmill
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Veracyte Announces Third Quarter 2025 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Biotech ↗
Veracyte (VCYT) offers affordable growth with strong earnings, a solid balance sheet, and reasonable valuation in the biotech sector. 
Via Chartmill
News headline image
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Inc (NASDAQ:VCYT) Presents a Strong Growth and Breakout Opportunity ↗
Veracyte (VCYT) stock analysis shows strong growth potential with 20% revenue growth, zero debt, and a bullish technical setup for a breakout. 
Via Chartmill
News headline image
Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Cancer Diagnostics ↗
Veracyte (VCYT) offers affordable growth with strong revenue & earnings expansion, a solid debt-free balance sheet, and reasonable valuation for the biotech sector. 
Via Chartmill
News headline image
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Inc (NASDAQ:VCYT) Emerges as a Strong Value Pick with Solid Fundamentals and Growth Potential ↗
Veracyte (VCYT) emerges as a potential value stock with strong valuation, profitability, and growth metrics in the biotech sector, backed by solid financial health and cash flow potential. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.